Xenopat S.L.

Xenopat S.L. is a Spanish biotechnology company and contract research organization (CRO) specializing in oncology. It is a spin-off of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL), and the Bellvitge University Hospital (HUB). The company's core technology is the orthotopic implantation of human tumors in mice, which allows it to offer services that assist anticancer drug development and personalized cancer treatment. Xenopat operates in two main fields: Advanced Preclinical Services and Personalized Cancer Treatment. In the preclinical space, it offers researchers and drug development companies the OrthoXenoBank®, a collection of orthoxenografts® — orthotopic models of various tumor types including colorectal, lung, breast, ovarian, testicular, and pancreatic tumors. These models are characterized at histological and genetic levels and exhibit different sensitivities to diverse chemotherapies. Xenopat's services span the entire oncological drug development process, from basic preclinical steps through to commercialization, and include customized cell line generation, maximum tolerated dose determination, histopathological toxicity analysis, optimal drug combination identification, and co-clinical paired trials in humans and mice. In the personalized cancer treatment field, Xenopat offers healthcare professionals and patients the ability to generate an orthoxenograft® from a small fragment of a patient's tumor. This mouse model allows the testing of several drugs to find the best therapy for each individual patient, supporting personalized treatment decisions. As a private company, Xenopat is based in Spain and serves clients internationally. Its positioning is at the intersection of advanced preclinical research and clinical oncology, providing tools that bridge laboratory research and patient care.

Xenopat S.L. was established as a spin-off of the Catalan Institute of Oncology (ICO), the Bellvitge Biomedical Research Institute (IDIBELL), and the Bellvitge University Hospital (HUB). The company was built around the orthotopic implantation of human tumors in mice, a technique that allows human tumors to grow in a physiologically relevant environment. This technology underpins both its preclinical drug development services and its personalized cancer treatment offering. From its inception, Xenopat has focused on two main fields: Advanced Preclinical Services and Personalized Cancer Treatment. In the preclinical area, it developed the OrthoXenoBank®, a collection of orthoxenografts® covering multiple tumor types such as colorectal, lung, breast, ovarian, testicular, and pancreatic tumors. These models are characterized at histological and genetic levels and show varying sensitivities to chemotherapies, making them valuable tools for drug development. The company offers a strategic partnership through the entire oncological drug development process, from basic preclinical steps to commercialization. Its services include customized cell line generation, maximum tolerated dose determination, histopathological toxicity analysis, optimal drug combination identification, and co-clinical paired trials in humans and mice. In personalized cancer treatment, Xenopat enables the generation of an orthoxenograft® from a small fragment of a patient's tumor, allowing the testing of multiple drugs to identify the best therapy for that individual. This approach supports clinicians and patients in making informed treatment decisions. As of the available information, Xenopat remains an active private company based in Spain, serving researchers, drug development companies, healthcare professionals, and patients.

Xenopat positions itself as a provider of advanced preclinical and personalized oncology services, leveraging orthotopic patient-derived xenograft models to bridge preclinical drug development and clinical treatment selection.

• OrthoXenoBank®

  A collection of orthoxenografts® — orthotopic models of different tumor types including colorectal, lung, breast, ovarian, testicular and pancreatic tumors, characterized at histological and genetic levels with different sensitivities to diverse chemotherapies.

• orthoxenografts®

  Orthotopic models generated by implanting human tumor fragments into mice, used for preclinical drug testing and personalized cancer treatment selection.

• Advanced Preclinical Services

  Services for researchers and drug development companies, including customized cell line generation, maximum tolerated dose determination, histopathological toxicity analysis, optimal drug combination identification, and co-clinical paired trials.

• Personalized Cancer Treatment

  Generation of an orthoxenograft® from a patient's tumor to test multiple drugs and identify the best therapy for that individual.

1. 1Home - Xenopatxenopat.com
2. 2Advanced Preclinical Services - Xenopatxenopat.com
3. 3Xenopat S.L. - Wikidatawikidata.org